Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014

Eurosurveillance

Volumn , Issue 30, 2014, Pages

  Golparian, D ^a   Ohlsson, A K ^b   Janson, H ^c   Lidbrink, P ^b   Richtner, T ^d   Ekelund, O ^c   Fredlund, H ^a   Unemo, M ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; FEMALE; GONORRHEA; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; ORAL SEX; PHARYNGITIS; PHARYNX DISEASE; PHARYNX EXAMINATION; SINGLE DRUG DOSE; SWEDEN; UNPROTECTED SEX; UROGENITAL SYSTEM EXAMINATION;

EID: 85181419661     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: Past, evolution and future. Clin Microbiol Rev. 2014;27(3):587-613. http://dx.doi.org/10.1128/CMR.00010-14
2. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7(7):821-834. http://dx.doi.org/10.1586/eri.09.63
3. Lewis DA. The gonococcus fights back: Is this time a knock out? Sex Transm Infect. 2010;86(6):415-421. http://dx.doi.org/10.1136/sti.2010.042648
4. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7(12):1401-1422. http://dx.doi.org/10.2217/fmb.12.117
5. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309(2):163-170. http://dx.doi.org/10.1001/jama.2012.176575
6. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrobial Chemother. 2013;68(6):1267-1270. http://dx.doi.org/10.1093/jac/dkt034
7. Read PJ, Limnios EA, McNulty A, Whiley D, Lahra LM. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health. 2013;10(5):460-462. http://dx.doi.org/10.1071/SH13077
8. Chen YM, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68(6):1445-1447. http://dx.doi.org/10.1093/jac/dkt017
9. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273-1280. http://dx.doi.org/10.1128/AAC.05760-11
10. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538-3545. http://dx.doi.org/10.1128/AAC.00325-11
11. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67(8):1858-1860. http://dx.doi.org/10.1093/jac/dks162
12. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis. 2004;189(8):1497-1505. http://dx.doi.org/10.1086/383047
13. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18(3):pii=20358.
14. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. Basel: European Society of Clinical Microbiology and Infectious Diseases; 1 Jan 2014. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/B reakpoint_table_v_4.0.pdf
15. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas R. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009;53(9):3744-3751. http://dx.doi.org/10.1128/AAC.00304-09
16. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590-594.
17. Bignell C, Unemo M, European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85-92. http://dx.doi.org/10.1177/0956462412472837
18. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis. 1995;22(1):39-47. http://dx.doi.org/10.1097/00007435-199501000-00007
19. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamics rethink? J Antimicrob Chemother. 2010;65(10):2141-2148. http://dx.doi.org/10.1093/jac/dkq289
20. Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect. 2013;89(Suppl 4):iv52-iv56. http://dx.doi.org/10.1136/sextrans-2012-050913
21. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect. 2010;86(6):422-426. http://dx.doi.org/10.1136/sti.2010.044586